Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study
Wid Alyamani, Attiah Khobrani, Fawaz O. Alenazy, Yahya A. Alzahrani et autres
Background Ibrutinib is widely used in B-cell malignancies, yet real-world safety data remain heterogeneous, particularly in underrepresented regional populations. Objective To characterize the adverse-event profile and severity and explore factors associated with Grade 3–5 toxicity and permanent treatment discontinuation among patients receiving …
sa (code pays fourni par la source)